Öppna denna publikation i ny flik eller fönster >>Strike Pharma AB, Uppsala, Sweden; Department of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Strike Pharma AB, Uppsala, Sweden; Department of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.
KTH, Skolan för kemi, bioteknologi och hälsa (CBH), Proteinvetenskap, Läkemedelsutveckling. KTH, Centra, Science for Life Laboratory, SciLifeLab. Science for Life Laboratory, Drug Discovery and Development, Stockholm, Sweden.
KTH, Skolan för kemi, bioteknologi och hälsa (CBH), Proteinvetenskap, Läkemedelsutveckling. KTH, Centra, Science for Life Laboratory, SciLifeLab. Science for Life Laboratory, Drug Discovery and Development, Stockholm, Sweden.
KTH, Skolan för kemi, bioteknologi och hälsa (CBH), Proteinvetenskap. KTH, Centra, Science for Life Laboratory, SciLifeLab.
KTH, Skolan för kemi, bioteknologi och hälsa (CBH), Proteinvetenskap. KTH, Centra, Science for Life Laboratory, SciLifeLab.
KTH, Skolan för kemi, bioteknologi och hälsa (CBH), Proteinvetenskap, Läkemedelsutveckling. Science for Life Laboratory, Drug Discovery and Development, Stockholm, Sweden.
Strike Pharma AB, Uppsala, Sweden; SciCross AB, Skövde, Sweden.
KTH, Skolan för kemi, bioteknologi och hälsa (CBH), Proteinvetenskap, Proteinteknologi. Strike Pharma AB, Uppsala, Sweden.
Strike Pharma AB, Uppsala, Sweden; Department of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Visa övriga...
2024 (Engelska)Ingår i: Nature Communications, E-ISSN 2041-1723, Vol. 15, nr 1, artikel-id 9542Artikel i tidskrift (Refereegranskat) Published
Abstract [en]
Current antibody-based immunotherapy depends on tumor antigen shedding for proper T cell priming. Here we select a novel human CD40 agonistic drug candidate and generate a bispecific antibody, herein named BiA9*2_HF, that allows for rapid antibody-peptide conjugate formation. The format is designed to facilitate peptide antigen delivery to CD40 expressing cells combined with simultaneous CD40 agonistic activity. In vivo, the selected bispecific antibody BiA9*2_HF loaded with peptide cargos induces improved antigen-specific proliferation of CD8+ (10-15 fold) and CD4+ T cells (2-7 fold) over control in draining lymph nodes. In both virus-induced and neoantigen-based mouse tumor models, BiA9*2_HF demonstrates therapeutic efficacy and elevated safety profile, with complete tumor clearance, as well as measured abscopal impact on tumor growth. The BiA9*2_HF drug candidate can thus be utilized to tailor immunotherapeutics for cancer patients.
Ort, förlag, år, upplaga, sidor
Nature Research, 2024
Nationell ämneskategori
Immunologi inom det medicinska området Biokemi Molekylärbiologi Medicinsk bioteknologi (med inriktning mot cellbiologi (inklusive stamcellsbiologi), molekylärbiologi, mikrobiologi, biokemi eller biofarmaci) Cancer och onkologi
Identifikatorer
urn:nbn:se:kth:diva-356688 (URN)10.1038/s41467-024-53839-5 (DOI)001348514000014 ()39500897 (PubMedID)2-s2.0-85208602407 (Scopus ID)
Anmärkning
QC 20241122
2024-11-202024-11-202025-02-20Bibliografiskt granskad